...
首页> 外文期刊>Journal of Pharmacy and Pharmacology >Preparation and evaluation of a novel delayed-onset sustained-release system of propranolol hydrochloride.
【24h】

Preparation and evaluation of a novel delayed-onset sustained-release system of propranolol hydrochloride.

机译:盐酸普萘洛尔新型延迟发作缓释系统的制备和评价。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The objective of this work was to prepare and evaluate a new delayed-onset sustained-release system, comprising a sustained-release core tablet with hydroxypropyl methylcellulose as polymer matrix and an ethylcellulose/Eudragit L coating capable of delaying the drug release. The sustained core containing propranolol hydrochloride as the model drug was prepared by granulate tableting and the polymer coating was applied in a computer-controlled coating pan. The dissolution tests demonstrated that the in-vitro drug release was pH-dependent with sufficient gastric resistance, and the lag time (t(10%)) could be controlled by adjusting the coating level. Three dosage forms including commercial tablet, sustained-release tablet and the delayed-onset sustained-release tablet were administrated to six beagle dogs and the plasma levels of propranolol hydrochloride were measured with high-performance liquid chromatography. The delayed-onset sustained-release tablet had a lag time of 3.0 h in-vitro and 3.5 h in-vivo, and a t(max) of 7.0 h. The relative bioavailability for delayed-onset sustained-release tablet was 96.98% compared with commercial tablets. The results indicate that the new propranolol delayed-onset sustained-release system could achieve a relatively constant drug release followed by a programmed lag time, and this may provide a promising drug delivery form for chronopharmacotherapy of certain cardiovascular diseases.
机译:这项工作的目的是准备和评估一种新的延迟发作持续释放系统,该系统包括以羟丙基甲基纤维素为聚合物基质的持续释放核心片剂和能够延迟药物释放的乙基纤维素/ Eudragit L包衣。通过颗粒压片法制备包含盐酸普萘洛尔作为模型药物的持续核心,并将聚合物包衣涂覆在计算机控制的包衣锅中。溶出度测试表明,体外药物释放是pH依赖性的,具有足够的胃耐受性,并且滞后时间(t(10%))可以通过调节包衣水平来控制。将六种比格犬给药包括市售片剂,持续释放片剂和延迟发作持续释放片剂的三种剂型,并用高效液相色谱法测定盐酸普萘洛尔的血浆水平。延迟发作的缓释片剂的体外滞后时间为3.0 h,体内滞后时间为3.5 h,t(max)为7.0 h。与市售片剂相比,延迟发作缓释片剂的相对生物利用度为96.98%。结果表明,新的普萘洛尔延迟发作缓释系统可以实现相对恒定的药物释放,随后具有程序化的滞后时间,这可能为某些心血管疾病的慢性药物治疗提供有希望的药物递送形式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号